SCHEMBL6644694

SCHEMBL6644694

NC(=O)c1cc(F)c(F)c(OCF)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ DGAT1 O75907 1/20 0.36
▸ PARP10 Q53GL7 5/20 0.35
▸ PARP15 Q460N3 3/20 0.35
▸ AURKA O14965 1/20 0.35
▸ RPS6KB1 P23443 1/20 0.35
▸ MAPK1 P28482 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ PARP14 Q460N5 1/20 0.33
▸ CES2 O00748 1/20 0.32
▸ CES1 P23141 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ PARP1 P09874 2/20 0.32
▸ CTSV O60911 1/20 0.32
▸ CTSL P07711 1/20 0.32
▸ CTSB P07858 1/20 0.32
▸ CTSH P09668 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646364 0.80 KDM4E (0.39) MAPTHTTKDM4EALDH1A1MAPK1
SCHEMBL3337229 0.79 ROCK2 (0.38) HTTKDM4EALDH1A1DGAT1PARP10
SCHEMBL6647223 0.76 MAPT (0.33) MAPTHTTKDM4EALDH1A1MAPK1
SCHEMBL6648524 0.76 DGAT1 (0.36) MAPTHTTKDM4EALDH1A1DGAT1
SCHEMBL7011778 0.73 KEAP1 (0.35) MAPTKDM4EALDH1A1CTSVCTSL
SCHEMBL829400 0.73 DGAT1 (0.45) DGAT1CES2CES1ROCK2PARP1
SCHEMBL28085635 0.73 DGAT1 (0.45) DGAT1CES2CES1ROCK2PARP1
SCHEMBL23846429 0.72 TSHR (0.45) HTTPARP10PARP15MAPK1LMNA
SCHEMBL6647834 0.70 MAPK1 (0.56) MAPTHTTKDM4EALDH1A1MAPK1
SCHEMBL7014156 0.70 HSD17B10 (0.35) MAPTKDM4ECTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 — — EP disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 — — US disclosed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 MAPT 4486/4885HTT 4546/4885KDM4E 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback